Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Discovery of novel thiohydantoin derived AR antagonists: design, synthesis and biological evaluation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- By: ZHANG, Daoguang (Shandong University, Department of Medicinal Chemistry, Jinan, China)
- Co-author(s): Daoguang Zhang: Department of Medicinal Chemistry, Shandong University, Jinan, China
Solomon Asnake: The Life Science Center, Örebro University, Örebro, Sweden
Per-Erik Olsson: The Life Science Center, Örebro University, Örebro, Sweden
Guisen Zhao: Department of Medicinal Chemistry, Shandong University, Jinan, China
BackgroundsProstate cancer (PCa) is the most frequently diagnosed male cancer in western societies. Androgen receptor (AR) signaling provides the main driving force for the development of PCa, even for castration resistant PCa (CRPC), making AR a critical therapeutic target for the treatment of PCa.
AimsEnzalutamide (MDV3100), approved in 2012 by.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019